Christopher William Ogden MBBS MS FRCS(Ed) FRCS(Eng) FRCS(Urol) FEBU CURRICULUM VITAE

Transcription

1 Christopher William Ogden MBBS MS FRCS(Ed) FRCS(Eng) FRCS(Urol) FEBU CURRICULUM VITAE

2 Name: Christopher William Ogden NHS practice Address: Department of Urology Chelsea and Westminster Hospital 369 Fulham Road London Date of Birth: 15 th September 1960 Nationality: British Marital Status: Jo Katherine Ogden married 1989 Children: Isabel Maia Ogden, born:1992 Otis William George Ogden, born:1999 School: Haileybury and Imperial Services College Medical School: Charing Cross and Westminster Qualifications: MB BS University of London 1984 FRCS Edinburgh 1989 FRCS England 1990 MS University of London 1993 FRCS Urology 1995 FEBU 1996 Current Post: Consultant Urologist Chelsea and Westminster and St Mary s Hopitals Honorary Senior lecturer Imperial College London CMC No.: MDU NO.: D

3 Higher Surgical Training Registrar general and vascular training rotation between the Hammersmith and the West Middlesex University Hospital from Jan Dec 1990 Registrar Urology Charing Cross and Hammersmith Jan July 1993 Research Registrar Urology Charing Cross Hospital Jan Dec1992 Visiting Lecturer to Japan, Professor Yoshoio, Chairman of the Japanese Urological Association and Dept of Urology at the University of Tokyo and Professor Osamu Yoshida Kyoto University School of Medicine Nov-Dec 1992 Senior Registrar Urology West London training scheme between Charing Cross, St Mary s, St Helier and the Royal Marsden Hospitals Aug July1995 Urology Visiting Fellow sponsored by the Royal College of Surgeons 1995 Professor De Kernion, University of California Los Angeles, Dr Donald Skinner,University of Southern California Los Angeles, Dr Patrick Walsh John Hopkins Hospital Baltimore Dr J Paulson Duke University North Carolina Consultant Urologist Northwick park and St Mark s Hospitals. Jan 1996-Dec 2001 I developed the use of the perineal approach for radical prostatectomy and the Studer orthotopic bladder replacement following radical cystectomy, including females. I developed a combined perineal and abdomino-perineal approach for the treatment of locally advanced rectal cancer involving the prostate and this is thought to be a pioneering operation. Research Interests: I have successfully funded and supervised Four research fellows leading to the award of the MD thesis. I have patented my research.. My research is into identifying the reexpression of highly specific developmental genes involved in the early development of the embryo and the urogenital tract, my research group has found expression of PAX2 in prostate cancer and PAX5 in bladder cancer. I have explored the possible link between Human endogenous retrovirus encoded in the human genome and prostate cancer and

4 role of Dentritic cells in bladder cancer in particular in their role in BCG therapy with the aim of understanding the immunological response with the hope of developing more specific treatments. Clinical trials and evaluation include the monoclonal targeting of prostate cancer a phase II open-label trial to evaluate intravenous 3622W94 monoclonal antibody for the treatment of metastatic prostate cancer. The evaluation of primary and metastaic cancer of the prostate using radioimmunoscintigraphy with Indium-111 labeled CYT-356. Since November 2004 I have set up the first team in the Uk to be certified in Radical Robotic Prostatectomy using the Da Vinchi System. I Have been involved in the first treatments in the UK using High Intensity Focused Ultrasound to treat prostate cancer which is a day case treatment. Grants obtained since my appointment as consultant Royal College of Surgeons of England research fellowship full September 1997 Royal College of Surgeons of England research fellowship full grants September 1998 Prostate research campaign full grant June 1999 BMA research grant June 1999 The Prostate Research Campaign UK September 1991 The Peel Medical Research Trust January 2000 The Berkeley Fellowship June 2000 The Mason Medical Research Foundation December 2000 The British Urological Foundation Research Scholarship March 2001 The Ralph Shackman Trust September 2001 The Ralph Shackman Tust October 2001 Patent UK Patent No: IOCOT/P20348GB Application of PAX2 in diagnosis and its use as a possible therapeutic target in prostate cancer

5 PUBLICATIONS Single blind study of transurethral microwave thermotherapy (TUMT) vs Sham: The Initial results. Ogden CW, Johnson H, Reddy P, Ramsay JWA, Carter SStC. Urology 1992; The Klippel-Trenaunay syndrome associated with renal artery aneurysm. Ogden CW, Jackson JE. British Journal of Urology1993. A prospective study of Sham vs TUMT in symptomatic prostatic bladder outflow obstruction. Ogden CW, Reddy P, Johnson H, Ramsay JWA, Carter SStC. Lancet 1993; 341: Long term results of TUMT for benign prostatic obstruction. Carter SStC, Ogden CW, Reddy P, Patel A, Ramsay JWA. Urology 1992; 257. TUMT in the treatment of urinary retention due to prostatic bladder outflow obstruction. Beavan AJ, Ogden CW, Ramsay JWA, Carter SStC. Urology 1992;251. Experience of transurethral microwave thermotherapy for the treatment of benign prostatic obstruction. Carter SStC, Patel A, Beavan AJ, Ogden CW. Non-surgical treatment of BPH, S.I.U., Edited by JM Fitzpatrick; 1992: Sham vs TUMT a randomised study with cross over. Ogden CW, Reddy P, Johnson H, and Carter SStC. Journal of Urology 1993; 147:250A.

6 The clinical response to transurethral microwave thermotherapy is thermal dose dependent. Devonec M, Ogden CW, Perrin P, Carter SStC. Eur. Urol. 1993; 23: Microwave thermotherapy in benign prostatic hyperplasia. Devonec M, Ogden CW, Carter SSt. Current Opinion in Urology. 1993; 3: Factors affecting the achieved prostatic heat in TUMT- An interstitial thermometry study. Ogden CW, Boulnois JL, Carter SStC. Journal of Endouology 1993; 7:S122 A study of clinical outcome in symptomatic BPH related to the achieved prostatic temperatures during TUMT. Carter SStC, Ogden CW. Journal of Endourology. 1993; 7:S76. Thermokinetic modelling of microwave heating in BPH. Ogden CW, Carter SStC, Boulnois JL. Minimally invasive therapy. 1993;2:S6. Thermotherapy for BPH- The achieved temperature as an indicator of clinical outcome. Carter SStC, Ogden CW. Minimally invasive therapy. 1993;2:S12. Heating the Prostate Ogden CW. Technical aspects of prostate cancer treatment: the present and the future.1994;2:11-13.

7 Heat and the prostate from electrolysis to microwaves: Lessons from an historical perspective. Ogden CW. Journal of Urology. 1994;151:319A. Symptom score and flow rate: Independent parameters in clinical response to microwave thermotherapy. Jonas U, Ogden CW, De La Rosette J, Tubaro A, Trucchi A, Miano L, Hofner K, Debruyne F, Carter SStC. Journal of Urology 1994;151:326A. Intraprostatic temperature versus clinical outcome in T.U.M.T. is the response heatdose dependent Carter SStC, Ogden CW. Journal of Urology 1994;151:416A. The prediction of clinical outcome from thermotherapy by pressure-flow study. Results of a European multi centre study. Tubaro A, Ogden CW, De La Rosette J, Hofner K, Trucchi A, Miano L, Carter SStC, Jonas U, Debruyne F. Journal of Urology 1994;151:417A. The current controversy in the management of prostate cancer Ogden CW and Shearer RJ. Postgraduate Doctor 1995;18: The prediction of clinical outcome from thermotherapy by pressure-flow study. Results of a European multi centre study. Tubaro A, Carter SStC, De La Rosette J, Hofner K, Trucchi A, Ogden CW, Miano L, Valenti M, Jonas U, Debruyne F. Journal of Urology 1995;153:

8 Monoclonal antibody targeting of baldder cancer Ogden, CW., Sandle J., Fisher C., Horwich A., Woodhouse C., Dean C. Journal of Urology 1996;155:568A A 12 -month study of the placebo effect in TUMT De Wildt M, Hubregtse M, Ogden C, Carter S, Debruyne F, De la Rosette J. British Journal of Urology 1996;77: Multiple frequent recurrences in superficial transitional cell carcinoma of the bladder: Is survival compromised by a conservative management strategy? Hrouda D, Ogden CW, Morris S, Wanendeya N, Fisher C and Woodhouse CRJ. British Journal of Urology 1997;79: The genetic initiation, progression and prognostic markers in transitional cell carcinoma of the bladder. Adshead JM, Kessling AM and Ogden CW. British Journal of Urology 1998;82: The expression of PAX5 in human transitional cell carcinoma of the bladder - relationship with de-differentiation. Adshead JM, OgdenCW, Penny MA, Stuart ET, and Kessling AM. British Journal of Urology 1999;83: What is the role of radical perineal prostatectomy? Ogden CW. Challenges in Prostate cancer, Edited by W Bowsher, published by Blackwell Science. 2000

9 Expression Of The Developmental And Oncogenic PAX 2 Gene In Human Prostate Cancer Bijan Khoubehi, Anna M. Kessling, James M. Adshead, Gillian L. Smith, Richard D. Smith, Christopher W. Ogden. J Urol 2001 Jun;165(6 Pt 1):